Bray Capital Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $65.4K | Buy |
708
+1
| +0.1% | +$90 | 0.02% | 167 |
|
|
2024
Q3 | $59.2K | Buy |
707
+2
| +0.3% | +$153 | 0.01% | 173 |
|
|
2024
Q2 | $48.3K | Buy |
705
+3
| +0.4% | +$200 | 0.01% | 175 |
|
|
2024
Q1 | $51.5K | Buy |
702
+2
| +0.3% | +$154 | 0.01% | 175 |
|
|
2023
Q4 | $56.7K | Buy |
700
+1
| +0.1% | +$78 | 0.02% | 172 |
|
|
2023
Q3 | $52.3K | Buy |
699
+502
| +255% | +$38.6K | 0.02% | 170 |
|
|
2023
Q2 | $15.1K | Buy |
197
+2
| +1% | +$160 | ﹤0.01% | 222 |
|
|
2023
Q1 | $16.2K | Buy |
195
+2
| +1% | +$166 | ﹤0.01% | 228 |
|
|
2022
Q4 | $16.6K | Buy |
193
+2
| +1% | +$158 | 0.01% | 224 |
|
|
2022
Q3 | $12K | Buy |
191
+2
| +1% | +$126 | ﹤0.01% | 245 |
|
|
2022
Q2 | $12K | Buy |
189
+2
| +1% | +$124 | ﹤0.01% | 240 |
|
|
2022
Q1 | $11K | Buy |
187
+2
| +1% | +$128 | ﹤0.01% | 248 |
|
|
2021
Q4 | $13K | Buy |
185
+2
| +1% | +$138 | ﹤0.01% | 243 |
|
|
2021
Q3 | $13K | Buy |
183
+2
| +1% | +$141 | ﹤0.01% | 239 |
|
|
2021
Q2 | $12K | Sell |
181
-90
| -33% | -$6.01K | ﹤0.01% | 239 |
|
|
2021
Q1 | $18K | Buy |
271
+2
| +0.7% | +$129 | 0.01% | 229 |
|
|
2020
Q4 | $16K | Buy |
269
+94
| +54% | +$5.67K | ﹤0.01% | 233 |
|
|
2020
Q3 | $11K | Buy |
175
+2
| +1% | +$139 | ﹤0.01% | 235 |
|
|
2020
Q2 | $13K | Buy |
173
+1
| +0.6% | +$77 | 0.01% | 231 |
|
|
2020
Q1 | $13K | Buy |
172
+2
| +1% | +$138 | 0.01% | 223 |
|
|
2019
Q4 | $11K | Buy |
170
+1
| +0.6% | +$65 | ﹤0.01% | 242 |
|
|
2019
Q3 | $11K | Sell |
169
-2,668
| -94% | -$174K | ﹤0.01% | 249 |
|
|
2019
Q2 | $192K | Buy |
2,837
+2
| +0.1% | +$132 | 0.07% | 154 |
|
|
2019
Q1 | $184K | Buy |
2,835
+1
| +0% | +$66 | 0.08% | 151 |
|
|
2018
Q4 | $177K | Buy |
2,834
+2
| +0.1% | +$140 | 0.09% | 150 |
|
|
2018
Q3 | $219K | Buy |
2,832
+1
| +0% | +$76 | 0.1% | 131 |
|
|
2018
Q2 | $201K | Buy |
2,831
+2
| +0.1% | +$141 | 0.09% | 132 |
|
|
2018
Q1 | $213K | Buy |
+2,829
| New | +$225K | 0.1% | 132 |
|
|
2017
Q4 | – | Sell |
-2,670
| Closed | -$216K | – | 135 |
|
|
2017
Q3 | $216K | Buy |
+2,670
| New | +$204K | 0.11% | 113 |
|
|
2017
Q1 | – | Sell |
-7,530
| Closed | -$539K | – | 123 |
|
|
2016
Q4 | $539K | Sell |
7,530
-10
| -0.1% | -$743 | 0.32% | 66 |
|
|
2016
Q3 | $596K | Sell |
7,540
-775
| -9% | -$63K | 0.36% | 67 |
|
|
2016
Q2 | $693K | Buy |
8,315
+965
| +13% | +$85.6K | 0.43% | 65 |
|
|
2016
Q1 | $675K | Sell |
7,350
-1,600
| -18% | -$144K | 0.59% | 50 |
|
|
2015
Q4 | $906K | Buy |
8,950
+170
| +2% | +$17.7K | 0.57% | 56 |
|
|
2015
Q3 | $862K | Buy |
8,780
+1,675
| +24% | +$186K | 0.55% | 55 |
|
|
2015
Q2 | $832K | Buy |
7,105
+100
| +1% | +$10.9K | 0.48% | 68 |
|
|
2015
Q1 | $689K | Buy |
7,005
+2,075
| +42% | +$211K | 0.41% | 80 |
|
|
2014
Q4 | $465K | Buy |
+4,930
| New | +$510K | 0.3% | 94 |
|
Other funds holding GILD
Bray Capital Advisors's GILD Position: Q4 2024 in Review
Bray Capital Advisors increased its Gilead Sciences (GILD) stake by 0.14% in Q4 2024, buying an estimated $90 and bringing the position to 708 shares worth $65.4K. The position accounts for 0.02% of the portfolio, ranked #167.
Bray Capital Advisors first reported a position in GILD in Q4 2014 and has held it in 38 quarters since. The position peaked at $906K in Q4 2015. 1,887 funds tracked by Wall St. Rank hold GILD as of Q4 2024.
- Bray Capital Advisors held 708 shares of Gilead Sciences worth $65.4K as of Q4 2024.
- Bray Capital Advisors bought 1 Gilead Sciences share in Q4 2024, an estimated $90.
- Gilead Sciences made up 0.02% of Bray Capital Advisors's portfolio in Q4 2024, its #167 holding.
- Bray Capital Advisors first reported a position in Gilead Sciences in Q4 2014 and has held it in 38 quarters since.
- Bray Capital Advisors's Gilead Sciences position peaked at $906K in Q4 2015.
- 1,887 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2024.
Based on Bray Capital Advisors's 13F filing for Q4 2024, filed 3 Feb 2025.